ArticlePloS one2025
Mapping the experiences of adult cancer patients receiving chimeric antigen receptor T-cell (CAR-T) therapy: A scoping review protocol.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChimeric antigen receptor T-cell (CAR T) therapy is an advancement in cancer treatments, particularly for patients with haematological malignancies who have exhausted conventional therapies like chemotherapy and stem cell transplant. CAR-T therapy involves genetically engineering a patient's own T-cells to attack cancer cells. The development of CAR-T therapy increased survival rates in 30% to 80% of patients. Due to its novelty, CAR-T therapy can present unforeseen challenges that prolong the experience of living with cancer and its treatment journey. While CAR-T cell therapies have the potential to be curative, these innovative treatments are often accompanied by a significant symptom burden, primarily cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity (ICANS). METHODS AND ANALYSIS: The Arksey and O'Malley framework and the population, concept and context (PCC) framework will guide the development of this scoping review. The population of this review is adults (18 years of age and older). The concept scoped is experiences of patients in the context of CAR-T therapy. CINAHL, Medline (EBSCO), PsycINFO, EMBASE and Web of Science will be searched, including grey literature. Screening and data extraction will be conducted by two independent researchers following the inclusion criteria and The Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) checklist. The protocol has been registered on Open Science Framework on 13th of May 2025. STUDY STATUS: Record screening is currently ongoing and it is estimated to be completed by 21st of July 2025. Data extraction is estimated to commence on 22nd of July 2025 and to be completed by 4th of August 2025. Results are to be expected on 15th of August 2025. DISSEMINATION OF
findingsFindings will be disseminated to relevant healthcare services electronically, through oral or poster presentations, conferences, congresses and publications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.